Srdic Danica, Khawla Al Musalhi, Soldatovic Ivan, Nikolic Jelena, Jevtovic Djordje, Nair Devaki, Dragovic Gordana
1 Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade , Belgrade, Serbia .
2 Department of Clinical Biochemistry, Royal Free Hospital, University College London , London, United Kingdom .
Metab Syndr Relat Disord. 2017 Apr;15(3):153-159. doi: 10.1089/met.2016.0068. Epub 2017 Feb 16.
Leptin, adiponectin, and resistin may play an important role in the development of lipodystrophy (LD) in HIV/AIDS patients. The aim of this study was to correlate levels of leptin, adiponectin, and resistin between HIV/AIDS patients with LD and without lipodystrophy (non-LD), as well as between subgroups of LD [lipoatrophy (LA), lipohypertrophy (LH), and mixed fat redistribution (MFR)] and non-LD patients.
Cross-sectional study of 66 HIV/AIDS patients. Serum levels of leptin, adiponectin, and resistin were measured. The associations between adipocytokine levels and metabolic variables were estimated by Spearman correlation. Analysis of covariance with bootstrapping method was used to examine the relationship between adiponectin and leptin and lipodystrophy categories.
The LD was observed in 29 (44%) patients, while 15 (52%) of them had LA, 4 (14%) had LH, and 10 (34%) patients had MFR. No significant differences regarding leptin, adiponectin, and resistin levels, between LD and non-LD patients, were observed. LH patients had significantly higher levels of leptin and adiponectin in comparison with non-LD patients (P = 0.039, P = 0.011, respectively). Within the LD group, LA patients had significantly lower levels of leptin (LA vs. LH, P = 0.020; LA vs. MFR, P = 0.027), while LH patients had significantly higher levels of adiponectin (LH vs. LA, P = 0.027; LH vs. MFR, P = 0.028). Correlation of adiponectin with LD remains significant in the LH subgroup after adjustment for age, body mass index, cystatin-C, plasminogen activator inhibitor-1 (PAI-1), and interferon gamma (IFN-γ) (P = 0.001).
Adiponectin and leptin levels differ significantly between LH patients and non-LD patients, as well as between the LD subgroups. Adiponectin may be a more useful marker of LD in HIV/AIDS patients.
瘦素、脂联素和抵抗素可能在人类免疫缺陷病毒/获得性免疫综合征（HIV/AIDS）患者脂肪代谢障碍（LD）的发生发展中起重要作用。本研究旨在比较伴有和不伴有脂肪代谢障碍（非LD）的HIV/AIDS患者之间，以及脂肪代谢障碍各亚组[脂肪萎缩（LA）、脂肪肥大（LH）和混合性脂肪重新分布（MFR）]与非LD患者之间瘦素、脂联素和抵抗素的水平。
对66例HIV/AIDS患者进行横断面研究。检测血清瘦素、脂联素和抵抗素水平。采用Spearman相关性分析评估脂肪细胞因子水平与代谢变量之间的关联。采用协方差分析和自抽样法检验脂联素、瘦素与脂肪代谢障碍类型之间的关系。
29例（44%）患者出现脂肪代谢障碍，其中15例（52%）为脂肪萎缩，4例（14%）为脂肪肥大，10例（34%）为混合性脂肪重新分布。未观察到脂肪代谢障碍患者与非脂肪代谢障碍患者在瘦素、脂联素和抵抗素水平上的显著差异。与非LD患者相比，LH患者的瘦素和脂联素水平显著更高（分别为P = 0.039，P = 0.011）。在脂肪代谢障碍组中，LA患者的瘦素水平显著低于LH患者（LA与LH相比，P = 0.020；LA与MFR相比，P = 0.027），而LH患者的脂联素水平显著高于LA患者（LH与LA相比，P = 0.027；LH与MFR相比，P = 0.028）。在调整年龄、体重指数、胱抑素C、纤溶酶原激活物抑制剂-1（PAI-1）和干扰素γ（IFN-γ）后，脂联素与LH亚组中的脂肪代谢障碍仍具有显著相关性（P = 0.001）。
LH患者与非LD患者之间以及脂肪代谢障碍各亚组之间，脂联素和瘦素水平存在显著差异。脂联素可能是HIV/AIDS患者脂肪代谢障碍更有用的标志物。
